BRIEF-Cullinan Therapeutics Licenses Rights to Velinotamig

Reuters
05 Jun
BRIEF-<a href="https://laohu8.com/S/CGEM">Cullinan Therapeutics</a> Licenses Rights to Velinotamig

June 4 (Reuters) - Cullinan Therapeutics Inc CGEM.O:

  • CULLINAN THERAPEUTICS LICENSES RIGHTS TO VELINOTAMIG, A CLINICAL-STAGE BCMA-DIRECTED BISPECIFIC T CELL ENGAGER, FROM GENRIX BIO FOR DEVELOPMENT IN AUTOIMMUNE DISEASES

  • CULLINAN THERAPEUTICS INC - TO PAY $20 MILLION UPFRONT LICENSE FEE TO GENRIX BIO

  • CULLINAN THERAPEUTICS INC - GENRIX ELIGIBLE FOR UP TO $292 MILLION IN MILESTONES

  • CULLINAN THERAPEUTICS INC - EXPECTS CASH RESOURCES TO LAST INTO 2028

  • CULLINAN THERAPEUTICS : GENRIX TO RECEIVE UP TO AN ADDITIONAL $400M IN SALES-BASED MILESTONES

Source text: ID:nGNXc1sZxw

Further company coverage: CGEM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10